Federal Register of Legislation - Australian Government

Primary content

PB 40 of 2012 Arrangements as made
This instrument amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (No. PB 79 of 2011) to makes changes to the special arrangement relating to the efficient funding of chemotherapy.
Administered by: Health
Registered 25 Jun 2012
Tabling HistoryDate
Tabled HR28-Jun-2012
Tabled Senate29-Jun-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

PB 40 of 2012

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 5)

 

National Health Act 1953

___________________________________________________________________________

 

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.

Dated 20 June 2012

 

 

 

 

 

 

 

 

 

 

 

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

___________________________________________________________________

 

 

 

 

 

1              Name of Instrument

 

(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 5).

 

(2)                This Instrument may also be cited as PB 40 of 2012.

 

2             Commencement

                This Instrument commences on 1 July 2012.

3              Amendments to PB 79 of 2011

                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

 

 


Schedule 1                   Amendments

 

 

[1]    Section 3, Definition for diluent fee

omit:                    $4.75

substitute:          $4.83

[2]    Section 3, Definition for dispensing fee

omit:                    $6.42

substitute:          $6.52

[3]    Section 3, Definition for distribution fee

omit:                    $24

substitute:          $24.38

[4]    Section 3 Definition for preparation fee

omit:                    $40

substitute:          $40.64

[5]    Schedule 1 Part 1, entry for Bortezomib

substitute:

Bortezomib

Powder for injection 3.5 mg

Injection

Velcade

JC

MP

C3762 C3763 C3764 C3765 C3766 C3767

D                                   

 

[6]    Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 160 mg in 16 mL with manner of administration Injection and brand DBL Docetaxel Concentrated Injection, in the column headed ‘Circumstances’

insert after C3890:

C3892

 

[7]    Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 2 mL with manner of administration Injection and brand DBL Docetaxel Concentrated Injection, in the column headed ‘Circumstances’

insert after C3890:

C3892

[8]    Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 8 mL with manner of administration Injection and brand DBL Docetaxel Concentrated Injection, in the column headed ‘Circumstances’

insert after C3890:

C3892

[9]    Schedule 1 Part 1, after entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL with manner of administration Injection and brand Irinotecan Actavis 500

insert in the columns in the order indicated:

 

 

 

Irinotecan Alphapharm

AF

MP

C3184

D

 

[10]  Schedule 2, after entry for Ondansetron in the form Tablet 4 mg (as hydrochloride dihydrate) with manner of administration Oral and brand Zofran

insert in the columns in the order indicated:

 

 

 

Zondan

GM

EMP

C3050

 

4

0

 

 

[11]  Schedule 2, after entry for Ondansetron in the form Tablet 8 mg (as hydrochloride dihydrate) with manner of administration Oral and brand Zofran

insert in the columns in the order indicated:

 

 

 

Zondan

GM

EMP

C3050

 

4

0

 

 

[12]  Schedule 2, after entry for Ondansetron in the form Tablet (orally disintegrating) 4 mg with manner of administration Oral and brand Ondansetron ODT-DRLA

insert in the columns in the order indicated:

 

 

 

Onsetron ODT 4

WQ

EMP

C3050

 

4

0

 

 

[13]  Schedule 2, after entry for Ondansetron in the form Tablet (orally disintegrating) 8 mg with manner of administration Oral and brand Ondansetron ODT-DRLA

insert in the columns in the order indicated:

 

 

 

Onsetron ODT 8

WQ

EMP

C3050

 

4

0

 

 

 

[14]  Schedule 3, after entry for GK

insert in the columns in the order indicated:

GM

Ascent Pharma Pty Ltd

 68 118 734 795

 

[15]  Schedule 3, entry for GZ

substitute:

GZ

sanofi-aventis Australia Pty Ltd

 31 008 558 807

 

 

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.